4D Molecular Therapeutics, Inc. (FDMT) Market Cap & Valuation Ratios
4D Molecular Therapeutics, Inc. (FDMT) has a market cap of $779.5M and a price-to-sales ratio of 8.5, with earnings according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
FDMT4D Molecular Therapeutics, Inc.Follow FDMT — free
—
Price chart with a free account
- Market cap
- 779.5M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 11 Nov, in 18 days
Peers
biotechnology · nearest by market cap · trailing 12 months| Company | Mkt cap, $B | P/E | EV/Sales | EV/EBITDA | FCF yield | Rev. growth | Op. margin | ROIC |
|---|---|---|---|---|---|---|---|---|
| FDMT | 0.8 | — | 4.8 | — | — | — | -214% | -56% |
| ALMS | 0.9 | — | 110.0 | — | — | — | — | -127% |
| AKTS | 0.9 | — | — | — | — | — | — | — |
| SVRA | 0.9 | — | — | — | -12.8% | — | — | -109% |
| ANRO | 0.9 | — | — | — | -8.0% | — | — | — |
| KURA | 0.9 | — | 4.5 | — | -13.7% | +25% | -412% | — |
| ABUS | 0.8 | 5.3 | 4.1 | 5.0 | -3.0% | +1079% | 82% | 83% |
| ARDX | 0.8 | — | 1.6 | — | -2.3% | +17% | -8% | -13% |
| ANNX | 0.8 | — | — | — | — | — | — | — |
| GERN | 0.7 | — | — | — | — | — | — | -18% |
| SANA | 0.7 | — | — | — | — | — | — | -294% |
| Median of these 10 | 5.3 | 4.3 | 5.0 | -8.0% | +25% | -8% | -63% |
; EV/Sales 4.8 vs. 4.3.
Growth vs. price
each dot a company · hover or tap for values4D Molecular Therapeutics, Inc. — questions
- What is 4D Molecular Therapeutics, Inc.'s market cap?
- $779.5M.
- What is 4D Molecular Therapeutics, Inc.'s price-to-sales ratio?
- 8.5.
Every figure on this page comes from 4D Molecular Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.